Axitinib
- Generic Name
- Axitinib
- Brand Names
- Inlyta, Axitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18N4OS
- CAS Number
- 319460-85-0
- Unique Ingredient Identifier
- C9LVQ0YUXG
- Background
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation V...
- Indication
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Thyroid cancer
- Associated Therapies
- First Line Chemotherapy
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT00828919
- Locations
- 🇮🇹
Fondazione IRCCS, Istituto Nazionale Tumori, S.S.D Oncologia Medica dei Tumori testa-collo, Milano, Italy
🇨🇿Nemocnice Na Bulovce, Praha, Czechia
🇫🇷Hopital de la Pitie Salpetriere, Paris Cedex 13, France
Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 180
- Registration Number
- NCT00768755
- Locations
- 🇬🇧
Pfizer Investigational Site, Poole, United Kingdom
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1520
- Registration Number
- NCT00700258
- Locations
- 🇩🇪
Office of Detlef Muller, Bautzen, Germany
🇩🇪Klotz, Weiden, Germany
🇩🇪Carsten Lange, Bernburg, Germany
Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2004-10-14
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00094094
- Locations
- 🇩🇪
Pfizer Investigational Site, Gauting, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.